Index > Vol. 89/2009 > Iss. 3/May > pp. 288-291 > Abstract
Clinical Report | Psoriasis and autoimmune diseases, Drug development and adverse reactions

Effect of Calcipotriol on Etanercept Partial Responder Psoriasis Vulgaris and Psoriatic Arthritis Patients

doi: 10.2340/00015555-0585

Abstract:

Patients who respond only partially to etanercept may require additional treatments that act synergistically to improve their therapeutic response while at the same time reducing the dose required and the risk of side-effects. The aim of this study was to evaluate the effecti veness of topical calcipotriol in etanercept partial responder patients. We enrolled 120 patients affected by psoriasis vulgaris and psoriatic arthritis. A 50 mg dose of etanercept was administered twice weekly for the first 12 weeks, followed by a 25 mg dose twice weekly for an additional 12 weeks. At week 12, for 45 patients who had not achieved PASI 50, calcipotriol cream was also prescribed twice daily for 4 weeks and then once daily for a further 8 weeks. At week 24, of the 45 patients in the
group treated with etanercept plus calcipotriol, 14 (31.1%) had achieved PASI 75, and 23 PASI 50, while 8 (17.7%) had dropped out of therapy; of the 75 patients who continued etanercept in monotherapy with a 25 mg dose twice weekly for another 12 weeks, 71 (94.6%) had achieved PASI 50 and 57 (76.0%) PASI 75. The application of calcipotriol in etanercept partial responder patients had therefore helped 37 out of 120 patients (31%) achieve at least PASI 50. This is the first report about the controlled combination of topical calcipotriol and etanercept in a large group of psoriatic patients. The efficacy and cost-effectiveness of the combined treatment is evidenced by the good response shown at week 24 by a group of etanercept low-responder patients using drugs sparingly and limiting likely toxicity.

Authors:

Elena Campione, Annamaria Mazzotta, Evelin Jasmine Paternò, Laura Diluvio, Joerg Christoph Prinz and Sergio Chimenti

Key words:

combined therapy; psoriasis; biologic drugs; analogue vitamin D.

References

  1. Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002; 301: 418–426. Link to article
  2. Goffe B, Clay Cather J. Etanerept: an overview. J Am Acad Dermatol 2003; 49: 105–111.
  3. Baugh JA, Bucala R. Mechanisms for modulating TNF in immune inflammatory disease. Curr Opin Drug Discov Devel 2001; 4: 635–650.
  4. Stern RS. A promising step forward in psoriasis therapy. JAMA 2003; 290: 3133–3135. Link to article
  5. Mease PJ, Goffe BS, Metz J, Vanderstoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356: 385–390. Link to article
  6. McCormack PL, Wellington K. Etanercept: in ankylosing spondylitis. BioDrugs 2004; 18: 199–205. Link to article
  7. Scheinfeld N. Therapy-resistant psoriasis treated with alefacept and subsequent narrow band ultraviolet B phototherapy with total clearing of psoriasis. Dermatol Online J 2005; 11: 7.
  8. Lee YH, Woo JH, Rho YH, Choi SJ, Ji JD, Song GS. Meta-analysis of the combination of TNF inhibitors plus MTX compared to MTX monotherapy, and the adjusted indirect comparison of TNF inhibitors in patients suffering from active rheumatoid arthritis. Rheumatol Int 2008; 28: 553–559 . Link to article
  9. Van de Kerkhof PCM, Camvazard F, Hutchinson PE, Haneke E, Wong E, Souteyrand P, et al. The effect of addition of calcipotriol ointment (50 g/g) to acitretin therapy in psoriasis. Br J Dermatol 1998; 138: 84–89. Link to article
  10. Kokelj F, Torsello P, Plozzer C. Calcipotriol improves the efficacy of cyclosporine in the treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 1998; 10: 143–146. Link to article
  11. De Jong EM, Mork NJ, Sijger MM, De La Brassine M, Lauharanta J, Jansen CT, et al. The combination of calcipotriol and methotrexate compared with methotrexate and vehicle in psoriasis: results of a multicentre placebo-controlled randomised trial. Br J Dermatol 2003; 148: 318–325. Link to article
  12. Van Duijnhoven MWFM, Krver JEM, Vissers WHPM, Van Vlijmen-Willems IMJJ, Pasch MC, Van Erp PEJ, et al. Effect of calcipotriol on epidermal cell populations in alefacept-treated psoriatic lesions. J Eur Acad Dermatol Venereol 2006; 20: 27–33. Link to article
  13. Guilhou JJ. The therapeutic effects of vitamin D3 and its analogues in psoriasis. Expert Opin Investig Drugs 1998; 7: 77–84. Link to article
  14. Kragballe K, Wildfang IL. Calcipotriol (MC 903), a novel vitamin D3 analogue stimulates terminal differentiation and inhibits proliferation of cultured human deratonocytes. Arch Dermatol Res 1990; 282: 164–167. Link to article
  15. Kristl J, Slanc P, Krasna M, Berlec A, Jeras M, Stukelj B. Calcipotriol affects keratinocyte proliferation by decreasing expression of early growth response-1 and polo-like kinase-2. Pharm Res 2008; 25: 521–529. Link to article
  16. Scott LJ, Dunn CJ and Goa KL. Calcipotriol ointment. A review of its use in the management of psoriasis. Am J Clin Dermatol 2001; 2: 95–120. Link to article
  17. Griffiths CEM, Christophers E, Barker JNWN, Chalmers RJG, Chimenti S, Krueger GG, et al. A classification of psoriasis vulgaris according to phenotype. Br J Dermatol 2007; 156: 258–262. Link to article
  18. Cohen JD, Zaltni S, Kaiser MJ, Bozonnat MC, Jorgensen C, Daurs JP, et al. Secondary addition of methotrexate to partial responders to etanercept alone is effective in severe rheumatoid arthritis. Ann Rheum Dis 2004; 63: 209–210. Link to article
  19. Klareskog L, van der Heijede D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 675–681. Link to article
  20. Legat FJ, Hofer A, Wackernagel A, Salmhofer W, Quehenberger F, Kerl H, et al. Narrowband UV-B phototherapy, alefacept, and clearance of psoriasis. Arch Dermatol. 2007; 143: 1016–1022. Link to article
  21. Gisondi P, Girolomoni G. Biologic therapies in psoriasis: a new therapeutic approach. Autoimmun Rev 2007; 6: 515–519. Link to article
  22. Boehncke WH, Brasie RA, Barker J, Chimenti S, Dauden E, de Rie M, et al. Recommendations on the use of etanercept in psoriasis: a European dermatology expert group consensus. J Eur Acad Dermatol Venereol 2006; 20: 988–998.